Protocols Report
183 Active protocols found listed by cancer typeReport Date: 2/13/2016 10:44:12 PM
Brain Cancer
Protocol IDPhaseLead OrganizationProtocol Title
A221101IIIALLIANCEA Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma
A221208IIALLIANCERandomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases
RTOG-0834IIINRGPHASE III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup Trial
Breast Cancer
Protocol IDPhaseLead OrganizationProtocol Title
A011104IIIALLIANCEEffect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
A011106IIIALLIANCEAlternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
A011202IIIALLIANCEA Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A211102IIIALLIANCETesting for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology after 12 months Metformin (1,1-dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control
A211201IIALLIANCEChange in Mammographic Density with Metformin Use: A Companion Study to NCIC Study MA.32
A221102IIIALLIANCERandomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias
CALGB-40903IIALLIANCE*** Alliance Only Study***
Phase II Study Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in SITU (DCIS)
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E2108IIIECOG-ACRINA Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer
E2112IIIECOG-ACRINA Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen
NSABP-B-43IIINRGA Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy
NSABP-B-47IIINRGA Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
NSABP-B-51IIINRGA Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
NSABP-B-52IIINRGA Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
NSABP-B-55IIINRGA Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
S0812IISWOG***This study will be permanently closed to participants who do not plan to submit core needle biopsies. The study will remain open until further notice, to participants who do plan to submit core needle breast biopsies.***
Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of High Dose Vitamin D in Premenopausal Women at High Risk for Breast Cancer Phase IIB
S1007IIISWOGA Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
S1202IIISWOGA Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
S1207IIISWOGPhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy
SCUSF-0806IISCUSFPhase II placebo-controlled trial of lisinopril and Coreg CR to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin)
Z11102OtherALLIANCEThis study is open to participation by all CTSU member sites.
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
CNS Metastases (see Metastatic Cancer)
Protocol IDPhaseLead OrganizationProtocol Title
N107CIIIALLIANCEA Phase III Trial of Post-Surgical Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
CNS Neoplasms (Primary Tumor)
Protocol IDPhaseLead OrganizationProtocol Title
RTOG-0925IINRGNatural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients with Supratentorial Low-Risk Grade II Glioma
CNS Primary
Protocol IDPhaseLead OrganizationProtocol Title
A071101IIALLIANCEA Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND# 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resective Recurrent Glioblastoma Multiforme (GBM)
Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
N0577IIIALLIANCEPhase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
N1174I/IIALLIANCEPhase 1/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme
Protocol IDPhaseLead OrganizationProtocol Title
A021202IIALLIANCEProspective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors
Gastrointestinal Cancer
Protocol IDPhaseLead OrganizationProtocol Title
A021101PilotALLIANCE***Temporary Suspension of this Study Effective February 4, 2014***
Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients with Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study
CALGB-80702IIIALLIANCEA phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancer
CALGB-80803IIALLIANCERandomized Phase II Trial Of Pet Scan-Directed Combined Modality Therapy In Esophageal Cancer
CITN11-01ICITNPhase I Study of Preoperative Gemcitabine Plus CP-870,893 (anti-CD40) Followed by Addition of CP-870,893 to Standard-of-Care Adjuvant Gemcitabine Followed by Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
E1208IIIECOG-ACRINA Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion
E2211IIECOG-ACRINA Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumor
E2212IIECOG-ACRINA Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver
E7208IIECOG-ACRINA Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Validation and comparison of biomarkers for the early detection of colorectal adenocarcinoma
N1048II/IIIALLIANCEA Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
NRG-GI001IIINRGRandomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
RTOG-0848IIINRGA Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
RTOG-1010IIINRGA Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment Of HER2-Overexpressing Esophageal Adenocarcinoma
RTOG-1112IIINRGRandomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
S0820IIISWOGA Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
S1201IISWOGA Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer
Genitourinary Cancer
Protocol IDPhaseLead OrganizationProtocol Title
A031201IIIALLIANCEA Phase III Trial of Enzalutamide (NSC#766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
A031203IIALLIANCE*** Alliance Only Study***
Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma
CALGB-70807IIIALLIANCEThe Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
CALGB-90203IIIALLIANCEA Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
CALGB-90601IIIALLIANCE A Randomized doubled-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab to gemcitabine, cisplatin, and placebo in patients with advanced transitional cell carcinoma
E2810IIIECOG-ACRINRandomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Subjects with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy
A Phase I/II Trial of a combination of Paclitaxel And Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer
RTOG-0534IIINRGA Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy
RTOG-0815IIINRGA Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
RTOG-0924IIINRGAndrogen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
RTOG-1115IIINRGPhase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer
S0931IIISWOGEVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.
S1011IIISWOGA Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.
S1216IIISWOGA Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Gynecologic Cancer
Protocol IDPhaseLead OrganizationProtocol Title
9434IIOH029Randomized phase II study of intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine® NSC #663249) cisplatin-radiochemotherapy versus intravenous cisplatin-radiochemotherapy in women diagnosed with stage IB-IVA cervical cancer and stage II-IVA vaginal cancer
CITN-05PilotCITNA Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
GOG-0238IINRGA Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent Bevacizumab (NSC #704865, IND #7921) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian tube Cancer (MEOC)
GOG-0258IIINRGA Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
GOG-0263IIINRGRandomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
GOG-0275IIINRGA Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
GOG-0277IIINRGA Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) v. Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
RTOG-1203IIINRGA Randomized Phase III Study of Standard VS IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)
Head and Neck Cancer
Protocol IDPhaseLead OrganizationProtocol Title
A091101I/IIALLIANCE*** New Patient Accrual Suspended Immediately - Effective, May 29, 2013***
*** Alliance Only Study***
TPF Induction Chemotherapy and Veliparib: A Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
A091305IIALLIANCEA Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, In Combination with Paclitaxel Versus Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer
E1305IIIECOG-ACRINA Phase III Randomized Trial of Cisplatin and Docetaxel with or without Bevacizumab In Patients with Recurrent or Metastatic Head and Neck Cancer
E1311IIECOG-ACRINA randomized phase II trial of Afatinib (BIBW2992) as adjuvant therapy following chemoradiation in patients with head and neck squamous cell carcinoma at high risk of recurrence
E3311IIECOG-ACRINPhase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
NRG-HN001II/IIINRGRandomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
RTOG-0912IINRGA Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
RTOG-0920IIINRGA Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
RTOG-1008IINRGA Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
RTOG-1016IIINRG***CLOSED to accrual EFFECTIVE 07/31/2014 at 5PM EDT***
***The quality of life (QOL) component has met its accrual objective (400 patients) and closed to accrual on 02/28/13. The trial remains open to accrual to the treatment and translational research components.***
Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
RTOG-1216II/IIINRGRandomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Cetuximab and Docetaxel for High-Risk Squamous Cell Cancer of the Head and Neck
RTOG-1221IINRGRandomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery followed by Risk-Based IMRT and Weekly Cisplatin versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer
Protocol IDPhaseLead OrganizationProtocol Title
8854IINY018Randomized Phase II Study of Epigenetic Priming Using Decitabine with Induction Chemotherapy in Patients with Acute Myelogenous Leukemia (AML)
A041202IIIALLIANCEA Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
CALGB-10701IIALLIANCEA Phase II Study of Dasatinib (Sprycel) (IND #73969, NSC #732517) as Primary Therapy followed by Transplantation for Adults ≥ 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
E1910IIIECOG-ACRINA Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
E1912IIIECOG-ACRINA Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
E2905IIIECOG-ACRINRandomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
E2906IIIECOG-ACRINPhase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytosine Arabinoside Induction and Intermediate Dose Cytosine Arabinoside Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age Greater Than or Equal to 60 Years).
S1117IISWOG***Study Temporarily Closed Effective 4/15/14 at 11:50 pm PST***
A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
S1203IIISWOGA Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) Versus IA with Vorinostat (NSC-701852) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Lung Cancer
Protocol IDPhaseLead OrganizationProtocol Title
A081105IIIALLIANCERandomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
CALGB-140503IIIALLIANCEA Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<=2 cm) Peripheral Non-Small Cell Lung Cancer
CALGB-30610IIIALLIANCEPhase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
CALGB-30901IIALLIANCERandomized phase II study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first-line chemotherapy
CALGB-31102IALLIANCE***Cohort 4 was opened to accrual effective December 4, 2013***
***Study Temporarily Suspended Effective October 17, 2013***
***Limited Participation Study***
Phase I Study of Accelerated Hypofractionated Radiation Therapy with Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
E1512IIECOG-ACRINA Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC
E2511I/IIECOG-ACRINPhase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
E4512IIIECOG-ACRINA Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
E5508IIIECOG-ACRINRandomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed or Both Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Stage Non-Squamous Non-Small Cell Lung Cancer
RTOG-0937IINRGRandomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC)
RTOG-1306IINRGA Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
RTOG-1308IIINRGPhase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
S0819IIISWOGA Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
S1400II/IIISWOGPhase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Protocol IDPhaseLead OrganizationProtocol Title
9177IINCICCR***Effective February 26, 2014 enrollment to the MYC positive DLBCL arm of the study (including plasmablastic lymphoma) is halted as the accrual target has been met. The study remains open for patients with untreated Burkitt lymphoma.***
Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
A051103IALLIANCE***Limited Access Study, Available Only to the Institutions Specified on the Protocol Cover Page***
A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular lymphoma
A051201I/IIALLIANCE*** Alliance Study: Phase I Select Site Participation - Phase II Available to Alliance Sites Only***
A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma
A051202IALLIANCE***Limited Access Study, Available Only to the Institutions Specified on the Protocol Cover Page***
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
CALGB-50801IIALLIANCE*** Alliance Only Study***
A Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
CALGB-50904IIALLIANCE*** Alliance Only Study***
A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib and Bendamustine in Patients with Untreated Follicular Lymphoma
CALGB-51101IIALLIANCEA Randomized Phase II Trial of Myeloablative versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
CITN-10IICITNA Phase II Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides / Sézary Syndrome
E1411IIECOG-ACRINIntergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
E1412IIECOG-ACRINRandomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
S1001IISWOGA Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
Protocol IDPhaseLead OrganizationProtocol Title
A091201IIALLIANCE*** Alliance Only Study***
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
CITN-04IICITNA Phase II Pilot Trial of an Indoleamine2,3, dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients with Advanced Melanoma
CITN-06-ALT-803ICITNA Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Melanoma
CITN-07-FLT3LIICITNA Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand
CITN11-02ICITNA Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer
E1609IIIECOG-ACRINE1609 is re-opened to pediatric accrual effective September 23, 2014. Adult accrual will remain closed.
E2607IIECOG-ACRINA Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas
Miscellaneous Neoplasm
Protocol IDPhaseLead OrganizationProtocol Title
A091202IIALLIANCEA Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma
A221301IIIALLIANCE***Alliance Sites Only***
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)
CITN-09IICITNA Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC)
E1Q11OtherECOG-ACRINEROS: Engendering Reproductive Health within Oncologic Survivorship
Multiple Cancers
Protocol IDPhaseLead OrganizationProtocol Title
8233IIMPCA Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer
9571ILAO-TX035A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer
9608ILAO-MN026A Phase I Trial of ABT-263, a Bcl-2 inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors
Protocol IDPhaseLead OrganizationProtocol Title
A061202I/IIALLIANCE*** Alliance Only Study***
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
E1A11IIIECOG-ACRINRandomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma
E3A06IIIECOG-ACRINRandomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic Smoldering Multiple Myeloma
S1211I/IISWOGA Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
S1304IISWOGA Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
Protocol IDPhaseLead OrganizationProtocol Title
CALGB-9665OtherALLIANCE*** Alliance Only Study***
The Alliance Hematologic Malignancy Biorepository
Protocol IDPhaseLead OrganizationProtocol Title
A091102IIALLIANCE*** Alliance Only Study***
A Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
A091105IIIALLIANCEA Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
AEWS1031IIICOGA Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma